Robotic Assisted Bronchoscopy Systems Market

According to Stratistics MRC, the Global Robotic-Assisted Bronchoscopy Systems Market is accounted for $0.9 billion in 2026 and is expected to reach $3.2 billion by 2034 growing at a CAGR of 17.2% during the forecast period. The Robotic-Assisted Bronchoscopy Systems Market encompasses advanced minimally invasive pulmonary diagnostic technologies that combine robotic catheter navigation, medical imaging, and precision biopsy instruments to access peripheral lung lesions. Increasing lung cancer prevalence, expanding pulmonary nodule screening programs, and growing demand for accurate tissue diagnosis are supporting market development. Innovations in electromagnetic navigation, fiber-optic shape sensing, and image-guided bronchoscopy improve procedural capabilities. Expanding healthcare infrastructure and investment in interventional pulmonology create additional growth opportunities.

Market Dynamics:

Driver:

Increasing lung cancer screening and demand for minimally invasive pulmonary diagnostics

Increasing lung cancer screening and demand for minimally invasive pulmonary diagnostics are driving market growth. Greater utilization of low-dose computed tomography screening increases detection of small pulmonary nodules requiring diagnostic evaluation. Robotic-assisted bronchoscopy systems enable controlled navigation through complex airway structures to access peripheral lung lesions. Growing demand for earlier lung cancer diagnosis encourages hospitals to invest in advanced bronchoscopic platforms. Improvements in robotic catheter stability, navigation accuracy, and image-guided biopsy techniques further support clinical adoption.

Restraint:

High equipment costs and specialized procedural training requirements

High equipment costs and specialized procedural training requirements restrain market growth. Robotic-assisted bronchoscopy platforms require substantial investment in robotic consoles, disposable instruments, navigation software, and maintenance services. Healthcare facilities must also provide specialized training for interventional pulmonologists and supporting clinical personnel. Integration with imaging equipment and hospital workflows can increase implementation complexity. Limited reimbursement availability and uncertainty regarding procedure-level cost effectiveness create additional barriers. Budget constraints among smaller hospitals further restrict widespread adoption.

Opportunity:

Expansion of image-guided robotic bronchoscopy for peripheral lung lesion diagnosis

Expansion of image-guided robotic bronchoscopy for peripheral lung lesion diagnosis presents significant growth opportunities. Healthcare providers are increasingly integrating robotic navigation with cone-beam computed tomography, augmented fluoroscopy, and radial endobronchial ultrasound to improve lesion localization. Growing demand for precise tissue sampling supports development of advanced biopsy instruments and navigation software. Innovations in real-time imaging and robotic catheter control may improve diagnostic performance. Strategic collaborations among medical device manufacturers and pulmonary care institutions encourage technology adoption.

Threat:

Competition from conventional bronchoscopy and alternative lung biopsy techniques

Competition from conventional bronchoscopy and alternative lung biopsy techniques poses significant challenges to market development. Robotic systems must demonstrate consistent diagnostic performance, acceptable procedural safety, and favorable economic outcomes compared with established approaches. Conventional navigational bronchoscopy, CT-guided transthoracic biopsy, and surgical sampling remain competing options. Potential complications, including pneumothorax and bleeding, require careful clinical evaluation. Regulatory requirements, reimbursement uncertainty, and rapid technological changes may further influence purchasing decisions and market competition.

Covid-19 Impact:

The COVID-19 pandemic disrupted bronchoscopy services through restrictions on aerosol-generating procedures, delayed lung cancer screening, and reduced elective diagnostic activities. Hospitals faced staffing shortages, infection control requirements, and interruptions in medical equipment supply chains. These challenges affected procedural volumes and installation schedules for robotic bronchoscopy systems. However, growing emphasis on early disease detection and efficient minimally invasive diagnostics encouraged continued technology development. Post-pandemic recovery in pulmonary care and expansion of lung cancer screening programs support renewed market growth.

The robotic bronchoscopy systems segment is expected to be the largest during the forecast period

The robotic bronchoscopy systems segment is expected to account for the largest market share during the forecast period due to substantial investment in advanced robotic navigation platforms and integrated diagnostic equipment. These systems combine robotic control, airway navigation, and specialized catheter technologies to improve access to peripheral pulmonary lesions. Growing hospital adoption of robotic-assisted procedures encourages equipment demand. Advances in navigation accuracy, catheter stability, and imaging integration improve clinical performance. Expanding interventional pulmonology infrastructure further strengthens segment prospects.

The bronchoscopic therapeutic interventions segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the bronchoscopic therapeutic interventions segment is predicted to witness the highest growth rate due to increasing investigation of robotic platforms for localized treatment of pulmonary lesions. These systems may support precise delivery of ablation devices and other therapeutic instruments to peripheral lung targets. Growing research into minimally invasive lung cancer treatment encourages technological innovation. Advances in navigation, real-time imaging, and robotic catheter control support procedural development. Expanding clinical validation could accelerate adoption across specialized pulmonary centers.

Region with largest share:

During the forecast period, North America is expected to hold the largest market share due to advanced pulmonary healthcare infrastructure, substantial medical technology investment, and widespread adoption of robotic-assisted procedures. The United States and Canada support robotic bronchoscopy through specialized hospitals, cancer treatment centers, and interventional pulmonology programs. Increasing lung cancer screening and demand for peripheral nodule diagnosis encourage regional growth. Established medical device manufacturers, clinical research networks, and healthcare reimbursement structures further strengthen North America's market position.

Region with highest CAGR:

Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding healthcare infrastructure, increasing lung cancer screening, and growing investment in minimally invasive diagnostic technologies. China, Japan, South Korea, India, and Australia are strengthening interventional pulmonology capabilities and adopting advanced medical imaging systems. Government-supported healthcare modernization and expanding hospital networks encourage investment. Improvements in robotic equipment accessibility, clinical training, and diagnostic infrastructure are expected to accelerate regional market development.

Key players in the market

Some of the key players in the Robotic-Assisted Bronchoscopy Systems Market include Intuitive Surgical, Inc., Johnson & Johnson, Noah Medical, Auris Health, Inc., Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Medtronic plc, Olympus Corporation, FUJIFILM Holdings Corporation, Ambu A/S, Boston Scientific Corporation, Veran Medical Technologies, Inc., Body Vision Medical Ltd., Broncus Medical, Inc., Nanjing MicroPort Medical Robotics Co., Ltd., Edge Medical, and Karl Storz SE & Co. KG.

Key Developments:

In October 2026, Intuitive Surgical, Inc. announced that clinicians across Europe had performed more than 10,000 robotic-assisted bronchoscopy procedures using its Ion endoluminal system since receiving CE marking in 2023. The milestone demonstrated expanding clinical adoption of shape-sensing robotic bronchoscopy for evaluating suspicious lung nodules and improving access to minimally invasive pulmonary diagnostics.

In September 2026, Noah Medical announced the first commercial procedure in Asia using its Galaxy robotic-assisted bronchoscopy system at Prince of Wales Hospital in Hong Kong. The development marked the transition from earlier clinical investigation to commercial implementation in the region, supporting the company's international expansion and broader adoption of integrated imaging and robotic navigation technologies.

In August 2026, Johnson & Johnson announced U.S. FDA 510(k) clearance for MONARCH QUEST 3, an updated software platform for robotic-assisted bronchoscopy. The release introduced AI-powered pulmonary nodule segmentation, enhanced registration and navigation capabilities, improved three-dimensional orientation, and broader compatibility with cone-beam CT imaging systems to support precise lung lesion targeting.

Components Covered:
• Robotic Bronchoscopy Systems
• Instruments & Accessories
• Software
• Services

System Types Covered:
• Single-Arm Robotic Bronchoscopy Systems
• Multi-Arm Robotic Bronchoscopy Systems
• Other System Types

Technologies Covered:
• Electromagnetic Navigation
• Fiber-Optic Shape-Sensing Navigation
• Other Navigation Technologies

Imaging Guidance Covered:
• Cone-Beam Computed Tomography (CBCT)
• Digital Tomosynthesis & Augmented Fluoroscopy
• Radial Endobronchial Ultrasound (rEBUS)
• Conventional Fluoroscopy
• Other Imaging Guidance

Applications Covered:
• Pulmonary Nodule Diagnosis
• Lung Cancer Diagnosis & Tissue Biopsy
• Peripheral Lung Lesion Sampling
• Bronchoscopic Therapeutic Interventions
• Other Applications

End Users Covered:
• Hospitals
• Specialty Pulmonology Clinics
• Cancer Treatment Centers
• Ambulatory Surgical Centers
• Other End Users

Regions Covered:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
o Netherlands
o Belgium
o Sweden
o Switzerland
o Poland
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Thailand
o Malaysia
o Singapore
o Vietnam
o Rest of Asia Pacific
• South America
o Brazil
o Argentina
o Colombia
o Chile
o Peru
o Rest of South America
• Rest of the World (RoW)
o Middle East
 Saudi Arabia
 United Arab Emirates
 Qatar
 Israel
 Rest of Middle East
o Africa
 South Africa
 Egypt
 Morocco
 Rest of Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances